GlassScriptPhysician profile
Thomas W Ozbirn
NPI 1811955156
$132,728.98
in general payments reported to CMS, 2019-2025
16 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $313 · 2021: $13K · 2022: $68K · 2023: $51K · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $2,533 · Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,750.00 |
| Travel and Lodging | $2,533.38 |
| Food and Beverage | $1,341.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $131,018.34 | 2019-2023 | Farxiga, Breztri |
| Vifor Pharma, INC. | $793.18 | 2019-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $344.30 | 2021-2025 | |
| Amgen INC. | $157.99 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $71.98 | 2019 | |
| Travere Therapeutics, INC. | $60.34 | 2022-2023 | |
| Glaxosmithkline, LLC. | $57.80 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $57.60 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $43.76 | 2022-2023 | Jynarque |
| Mallinckrodt Enterprises LLC | $28.34 | 2019 | |
| Akebia Therapeutics INC | $18.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.64 | 2019 | |
| Fresenius USA Marketing, INC. | $16.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $16.00 | 2020 | |
| Boston Scientific Corporation | $14.46 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ozbirn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.